Venture Capital

Diga-Talk Solutions names John K. Sullivan its new CBO, leveraging his 30 years in fire service to revolutionize mission-critical communications.

The biopharma company's strategic bid for non-dilutive funding could advance a first-in-class therapy for severe, untreated skin conditions.

NVIDIA invests billions in optics leader Coherent to secure the high-speed, US-made components needed to power the next generation of AI factories.

For millions suffering from relentless chronic cough with no approved treatments, Trevi Therapeutics' Haduvio offers a new possibility backed by strong clinical data.

With a $41M boost from a16z, Ease Health is using AI to unify a fractured behavioral health system, promising relief for overwhelmed providers.

Following a chaotic power outage, unions and city leaders rally against Waymo, demanding answers on public safety, job security, and regulatory oversight.

After a dramatic pivot and massive fundraising, Galecto will detail its new hematology pipeline at a key conference. Here’s what investors are watching.

Amid soaring uranium prices, Refined Energy begins its maiden drill program in Saskatchewan's prolific Athabasca Basin, a high-stakes bet on nuclear's future.

With a $6B M&A war chest and a new AI focus, Roper Technologies takes the stage at Morgan Stanley. Here’s what investors will be watching for.

In a strategic reverse merger with Rallybio, T-cell therapy innovator Candid Therapeutics secures over $505M to advance its groundbreaking autoimmune pipeline.

With major trials underway for its cancer and vision drugs, NovaBridge's upcoming investor presentation could be a pivotal moment for the biotech firm.

With a strong cash position and promising drug candidate, Apogee Therapeutics is advancing multiple trials to challenge the I&I market with a new therapy.

Riding high on U.S. success, GEEK BAR returns to Europe with a reusable vape, a strategic pivot as the continent wages war on disposable products.

Lynk Pharmaceuticals reports its oral drug zemprocitinib met all goals in a late-stage study for atopic dermatitis, offering rapid itch relief and a strong safety profile.

A key clinical milestone for its MS drug azer-cel nets Precision BioSciences $7.5M, extending its financial runway and boosting hope for patients.

A new DLA contract with REalloys seeks to onshore Samarium and Gadolinium production, vital for defense, using a breakthrough zero-waste technology.

Following strong shareholder support, Azimut Exploration launches a massive drilling campaign targeting deep gold potential and expanding known resources in Quebec.

With a strong cash runway and pivotal trials underway, Sionna Therapeutics aims to revolutionize CF treatment with a novel class of NBD1 stabilizer drugs.

With positive Phase 3 data for its first-in-class Stargardt disease drug and a massive new financing round, Belite Bio pivots toward commercialization.

AI firm MiniMax reports a 159% revenue surge alongside a massive paper loss, revealing the strange economics of AI growth and its global ambitions.